Provided by Tiger Trade Technology Pte. Ltd.

Daxor

10.14
+0.05000.50%
Post-market: 10.140.00000.00%16:04 EDT
Volume:9.22K
Turnover:93.37K
Market Cap:59.09M
PE:5.60
High:10.73
Open:10.73
Low:10.01
Close:10.09
52wk High:14.76
52wk Low:7.10
Shares:5.83M
Float Shares:2.97M
Volume Ratio:0.67
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.81
EPS(LYR):1.81
ROE:22.45%
ROA:-1.64%
PB:1.29
PE(LYR):5.59

Loading ...

Daxor announces SCCM 2026 clinical data; BVA detects 20% per hour median albumin escape rate due to weak correlations in capillary leak indexes

Reuters
·
Mar 26

Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions

GlobeNewswire
·
Mar 17

Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress

GlobeNewswire
·
Mar 10

Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026

GlobeNewswire
·
Mar 09

Maxim Group Sticks to Its Buy Rating for Daxor (DXR)

TIPRANKS
·
Mar 08

Daxor issues update in Letter to Shareholders

TIPRANKS
·
Mar 03

BRIEF-Daxor Corporation CEO And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders

Reuters
·
Mar 03

Daxor reports net asset value rises to 9 07 per share as of December 31 2025 not estimated

Reuters
·
Mar 03

Daxor Launches BVA Diagnostic Program in Southern Middle Tennessee

Reuters
·
Feb 24

Daxor initiated with a Buy at Lake Street

TIPRANKS
·
Feb 11

BRIEF-Daxor Corp Reaffirms Focus On Blood Volume Analysis Technology

Reuters
·
Feb 10

Daxor Corp: Announces Transition to Securities Exchange Act of 1934 Reporting Company

THOMSON REUTERS
·
Feb 10

Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business

GlobeNewswire
·
Feb 10

Daxor Files Legal Opinion Affirming Validity of Stock

TIPRANKS
·
Jan 27

Daxor Corporation Announces $9 Million Registered Direct Offering

GlobeNewswire
·
Jan 23

Daxor Releases Updated Investor Presentation to Public Markets

TIPRANKS
·
Jan 23

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

GlobeNewswire
·
Nov 25, 2025

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

GlobeNewswire
·
Oct 21, 2025

Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25

GlobeNewswire
·
Oct 15, 2025

Daxor Corporation Files Initial Statement of Beneficial Ownership for Chief Medical Officer John Jefferies

Reuters
·
Oct 03, 2025